Q1 2023 Earnings Estimate for bluebird bio, Inc. Issued By SVB Leerink (NASDAQ:BLUE)

bluebird bio, Inc. (NASDAQ:BLUE – Get Rating) – SVB Leerink issued their Q1 2023 earnings per share (EPS) estimates for bluebird bio in a research note issued on Monday, January 23rd. SVB Leerink analyst M. Foroohar expects that the biotechnology company will earn ($0.64) per share for the quarter. SVB Leerink currently has a “Market Perform” rating and a $8.00 target price on the stock. The consensus estimate for bluebird bio’s current full-year earnings is ($4.36) per share. SVB Leerink also issued estimates for bluebird bio’s Q2 2023 earnings at ($0.62) EPS and Q3 2023 earnings at ($0.58) EPS.

bluebird bio (NASDAQ:BLUE – Get Rating) last released its quarterly earnings results on Monday, November 7th. The biotechnology company reported ($0.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.28) by $0.36. The company had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $2.25 million. bluebird bio had a negative return on equity of 173.58% and a negative net margin of 8,828.28%.

Other analysts have also issued research reports about the company. Morgan Stanley upped their price objective on bluebird bio from $3.00 to $4.00 and gave the company an “underweight” rating in a report on Tuesday. Royal Bank of Canada cut their price objective on bluebird bio to $8.00 and set a “sector perform” rating for the company in a report on Tuesday, November 8th. Finally, StockNews.com started coverage on bluebird bio in a report on Wednesday, October 12th. They issued a “sell” rating for the company. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $6.75.

bluebird bio Stock Up 5.5 %

Shares of bluebird bio stock opened at $6.53 on Tuesday. The firm has a market cap of $541.49 million, a price-to-earnings ratio of -1.07 and a beta of 0.99. The business has a fifty day simple moving average of $7.40 and a 200-day simple moving average of $6.52. bluebird bio has a fifty-two week low of $2.87 and a fifty-two week high of $8.58.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of BLUE. Swiss National Bank raised its position in bluebird bio by 11.2% during the first quarter. Swiss National Bank now owns 165,807 shares of the biotechnology company’s stock valued at $804,000 after buying an additional 16,700 shares during the period. Raymond James & Associates acquired a new position in bluebird bio during the first quarter valued at $50,000. US Bancorp DE raised its position in bluebird bio by 82.9% during the first quarter. US Bancorp DE now owns 8,486 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 3,847 shares during the period. Bank of Montreal Can acquired a new position in bluebird bio in the 1st quarter worth about $58,000. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new position in bluebird bio in the 1st quarter worth about $1,081,000. 79.01% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Nick Leschly sold 4,290 shares of the company’s stock in a transaction on Wednesday, January 11th. The stock was sold at an average price of $7.80, for a total transaction of $33,462.00. Following the transaction, the director now directly owns 280,149 shares of the company’s stock, valued at $2,185,162.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 9,506 shares of company stock valued at $72,088 over the last three months. Insiders own 2.20% of the company’s stock.

About bluebird bio

(Get Rating)

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.